Literature DB >> 22993313

Novel vitamin D hydroxyderivatives inhibit melanoma growth and show differential effects on normal melanocytes.

Andrzej T Slominski1, Zorica Janjetovic, Tae-Kang Kim, Adam C Wright, Laura N Grese, Samuel J Riney, Minh N Nguyen, Robert C Tuckey.   

Abstract

BACKGROUND/AIMS: To test the activity of novel hydroxyvitamin D(3) analogs (20(OH)D(3), 20,23(OH)(2)D and 1,20(OH)(2)D(3)) on normal and malignant melanocytes in comparison to 1,25(OH)(2)D(3).
MATERIALS AND METHODS: Human epidermal melanocytes and human and hamster melanoma cells were used to measure effects on proliferation and colony formation in monolayer and soft agar. Cell morphology and melanogenesis were also analyzed. QPCR was used to measure gene expression.
RESULTS: Novel secosteroids inhibited proliferation and colony formation by melanoma cells in a similar fashion to 1,25(OH)(2)D(3), having no effect on melanogenesis. These effects were accompanied by ligand-induced translocation of VDR to the nucleus. In normal melanocytes 1α-hydroxyderivatives (1,25(OH)(2)D(3) and 1,20(OH)(2)D(3)) had stronger anti-proliferative effects than 20(OH)D(3) and 20,23(OH)(2)D(3), and inhibited dendrite formation. The cells tested expressed genes encoding VDR and enzymes that activate or inactivate vitamin D(3).
CONCLUSION: Novel secosteroids show potent anti-melanoma activity in vitro with 20(OH)D(3) and 20,23(OH)(2)D(3) being excellent candidates for pre-clinical testing.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22993313      PMCID: PMC3458587     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  43 in total

Review 1.  New vitamin D analogs as potential therapeutics in melanoma.

Authors:  Paulina Szyszka; Michal A Zmijewski; Andrzej T Slominski
Journal:  Expert Rev Anticancer Ther       Date:  2012-05       Impact factor: 4.512

2.  The potential role of vitamin D in the progression of benign and malignant melanocytic neoplasms.

Authors:  Joel Pinczewski; Andrzej Slominski
Journal:  Exp Dermatol       Date:  2010-10       Impact factor: 3.960

Review 3.  Vitamin D deficiency.

Authors:  Michael F Holick
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

4.  A new steroidal 5,7-diene derivative, 3beta-hydroxyandrosta-5,7-diene-17beta-carboxylic acid, shows potent anti-proliferative activity.

Authors:  Tae-Kang Kim; Jianjun Chen; Wei Li; Jordan Zjawiony; Duane Miller; Zorica Janjetovic; Robert C Tuckey; Andrzej Slominski
Journal:  Steroids       Date:  2009-12-16       Impact factor: 2.668

5.  Chemical synthesis of 20S-hydroxyvitamin D3, which shows antiproliferative activity.

Authors:  Wei Li; Jianjun Chen; Zorica Janjetovic; Tae-Kang Kim; Trevor Sweatman; Yan Lu; Jordan Zjawiony; Robert C Tuckey; Duane Miller; Andrzej Slominski
Journal:  Steroids       Date:  2010-06-11       Impact factor: 2.668

6.  Correlation between secosteroid-induced vitamin D receptor activity in melanoma cells and computer-modeled receptor binding strength.

Authors:  Tae-Kang Kim; Jin Wang; Zorica Janjetovic; Jianjun Chen; Robert C Tuckey; Minh N Nguyen; Edith K Y Tang; Duane Miller; Wei Li; Andrzej T Slominski
Journal:  Mol Cell Endocrinol       Date:  2012-04-21       Impact factor: 4.102

7.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors:  Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

8.  Products of vitamin D3 or 7-dehydrocholesterol metabolism by cytochrome P450scc show anti-leukemia effects, having low or absent calcemic activity.

Authors:  Andrzej T Slominski; Zorica Janjetovic; Brian E Fuller; Michal A Zmijewski; Robert C Tuckey; Minh N Nguyen; Trevor Sweatman; Wei Li; Jordan Zjawiony; Duane Miller; Tai C Chen; Gerard Lozanski; Michael F Holick
Journal:  PLoS One       Date:  2010-03-26       Impact factor: 3.240

9.  Pathways and products for the metabolism of vitamin D3 by cytochrome P450scc.

Authors:  Robert C Tuckey; Wei Li; Jordan K Zjawiony; Michal A Zmijewski; Minh N Nguyen; Trevor Sweatman; Duane Miller; Andrzej Slominski
Journal:  FEBS J       Date:  2008-04-10       Impact factor: 5.542

10.  Sequential metabolism of 7-dehydrocholesterol to steroidal 5,7-dienes in adrenal glands and its biological implication in the skin.

Authors:  Andrzej T Slominski; Michal A Zmijewski; Igor Semak; Trevor Sweatman; Zorica Janjetovic; Wei Li; Jordan K Zjawiony; Robert C Tuckey
Journal:  PLoS One       Date:  2009-02-03       Impact factor: 3.240

View more
  58 in total

1.  Total synthesis of biologically active 20S-hydroxyvitamin D3.

Authors:  Qinghui Wang; Zongtao Lin; Tae-Kang Kim; Andrzej T Slominski; Duane D Miller; Wei Li
Journal:  Steroids       Date:  2015-10-01       Impact factor: 2.668

2.  Metabolism of 20-hydroxyvitamin D3 and 20,23-dihydroxyvitamin D3 by rat and human CYP24A1.

Authors:  Elaine W Tieu; Wei Li; Jianjun Chen; Tae-Kang Kim; Dejian Ma; Andrzej T Slominski; Robert C Tuckey
Journal:  J Steroid Biochem Mol Biol       Date:  2015-02-26       Impact factor: 4.292

Review 3.  The role of CYP11A1 in the production of vitamin D metabolites and their role in the regulation of epidermal functions.

Authors:  Andrzej T Slominski; Tae-Kang Kim; Wei Li; Ae-Kyung Yi; Arnold Postlethwaite; Robert C Tuckey
Journal:  J Steroid Biochem Mol Biol       Date:  2013-10-28       Impact factor: 4.292

Review 4.  Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management.

Authors:  Andrzej T Slominski; Anna A Brożyna; Michal A Zmijewski; Wojciech Jóźwicki; Anton M Jetten; Rebecca S Mason; Robert C Tuckey; Craig A Elmets
Journal:  Lab Invest       Date:  2017-02-20       Impact factor: 5.662

5.  Noncalcemic Vitamin D Hydroxyderivatives Inhibit Human Oral Squamous Cell Carcinoma and Down-regulate Hedgehog and WNT/β-Catenin Pathways.

Authors:  Allen S W Oak; Georgeta Bocheva; Tae-Kang Kim; Anna A Brożyna; Zorica Janjetovic; Mohammad Athar; Robert C Tuckey; Andrzej T Slominski
Journal:  Anticancer Res       Date:  2020-05       Impact factor: 2.480

6.  Decreased VDR expression in cutaneous melanomas as marker of tumor progression: new data and analyses.

Authors:  Anna A Brożyna; Wojciech Jóźwicki; Andrzej T Slominski
Journal:  Anticancer Res       Date:  2014-06       Impact factor: 2.480

7.  Novel vitamin D analogs as potential therapeutics: metabolism, toxicity profiling, and antiproliferative activity.

Authors:  Jianjun Chen; Jin Wang; Tae-Kang Kim; Elaine W Tieu; Edith K Y Tang; Zongtao Lin; Dianne Kovacic; Duane D Miller; Arnold Postlethwaite; Robert C Tuckey; Andrzej T Slominski; Wei Li
Journal:  Anticancer Res       Date:  2014-05       Impact factor: 2.480

Review 8.  Endogenously produced nonclassical vitamin D hydroxy-metabolites act as "biased" agonists on VDR and inverse agonists on RORα and RORγ.

Authors:  Andrzej T Slominski; Tae-Kang Kim; Judith V Hobrath; Allen S W Oak; Edith K Y Tang; Elaine W Tieu; Wei Li; Robert C Tuckey; Anton M Jetten
Journal:  J Steroid Biochem Mol Biol       Date:  2016-09-28       Impact factor: 4.292

9.  Hydroxylation of CYP11A1-derived products of vitamin D3 metabolism by human and mouse CYP27B1.

Authors:  Edith K Y Tang; Jianjun Chen; Zorica Janjetovic; Elaine W Tieu; Andrzej T Slominski; Wei Li; Robert C Tuckey
Journal:  Drug Metab Dispos       Date:  2013-03-01       Impact factor: 3.922

10.  Design, Synthesis and Biological Activities of Novel Gemini 20S-Hydroxyvitamin D3 Analogs.

Authors:  Zongtao Lin; Srinivasa R Marepally; Tae-Kang Kim; Zorica Janjetovic; Allen Sw Oak; Arnold E Postlethwaite; Linda K Myers; Robert C Tuckey; Andrzej T Slominski; Duane D Miller; Wei Li
Journal:  Anticancer Res       Date:  2016-03       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.